Mode
Text Size
Log in / Sign up
Phase 3 N=213 Randomized Quadruple-blind Treatment

Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain

Chronic Pain

Enrolled (actual)
213
Serious AEs
2.0%
Results posted
Dec 2010
Primary outcome: Primary: Pain Intensity Difference (PID) at 15 Minutes Post-treatment (PID15) — 0.88; 0.76 Units on scale — p=0.0004

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Fentanyl Buccal Tablet (Drug); Immediate release oxycodone (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Cephalon
Primary completion
Nov 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Pain Intensity Difference (PID) at 15 Minutes Post-treatment (PID15)
0.88; 0.76 0.0004 sig
SECONDARY
Pain Intensity Difference (PID) at 5 Minutes Post-treatment
.08; .06 0.2242
SECONDARY
Pain Intensity Difference (PID) at 10 Minutes Post-treatment
.35; .29 0.0106 sig
SECONDARY
Pain Intensity Difference (PID) at 30 Minutes Post-treatment
2.10; 1.79 <0.0001 sig
SECONDARY
Pain Intensity Difference (PID) at 45 Minutes Post-treatment
3.13; 2.85 <0.0001 sig
SECONDARY
Pain Intensity Difference (PID) at 60 Minutes Post-treatment
3.65; 3.48 0.0002 sig
SECONDARY
Percentage Change in Pain Intensity Difference (% PID) at 5 Minutes Post-treatment
1.01; 0.73
SECONDARY
Percentage Change in Pain Intensity Difference (% PID) at 10 Minutes Post-treatment
4.83; 3.89
SECONDARY
Percentage Change in Pain Intensity Difference (% PID) at 15 Minutes Post-treatment
12.38; 10.38
SECONDARY
Percentage Change in Pain Intensity Difference (% PID) at 30 Minutes Post-treatment
29.72; 25.03
SECONDARY
Percentage Change in Pain Intensity Difference (% PID) at 45 Minutes Post-treatment
44.84; 40.49
SECONDARY
Percentage Change in Pain Intensity Difference (% PID) at 60 Minutes Post-treatment
52.61; 49.47
SECONDARY
Sum of Pain Intensity Difference at 30 Minutes Post-treatment (SPID30)
2.54; 2.16 <0.0001 sig
SECONDARY
Sum of Pain Intensity Difference at 60 Minutes Post-treatment (SPID60)
9.32; 8.50 <0.0001 sig
SECONDARY
Pain Relief (PR) Score at 5 Minutes Post-treatment
0.11; 0.10 0.5575
SECONDARY
Pain Relief Score at 10 Minutes Post-treatment
0.32; 0.26 0.0981
SECONDARY
Pain Relief Score at 15 Minutes Post-treatment
0.68; 0.56 0.0443 sig
SECONDARY
Pain Relief Score at 30 Minutes Post-treatment
1.48; 1.22 0.0004 sig
SECONDARY
Pain Relief Score at 45 Minutes Post-treatment
2.14; 1.90 0.0001 sig
SECONDARY
Pain Relief Score at 60 Minutes Post-treatment
2.44; 2.27 0.0018 sig
SECONDARY
Total Pain Relief at 60 Minutes (TOTPAR60)
6.43; 5.70 <0.0001 sig
SECONDARY
Percent Total Pain Relief at 60 Minutes Posttreatment (%TOTPAR)
40.11; 35.59
SECONDARY
Time to Any Pain Relief (APR) by Treatment - <= 5 Minutes
55; 50 0.7012
SECONDARY
Time to Any Pain Relief (APR) by Treatment <=10 Minutes
226; 219 0.6545
SECONDARY
Time to Any Pain Relief (APR) by Treatment <=15 Minutes
515; 451 0.0407 sig
SECONDARY
Time to Any Pain Relief (APR) by Treatment <=30 Minutes
1004; 877 0.0007 sig
SECONDARY
Time to Any Pain Relief (APR) by Treatment <=45 Minutes
1217; 1150 0.0372 sig
SECONDARY
Time to Any Pain Relief (APR) by Treatment <=60 Minutes
1271; 1239 0.3099
SECONDARY
Time to Meaningful Pain Relief (MPR) by Treatment - <= 5 Minutes
21; 26 0.5777
SECONDARY
Time to Meaningful Pain Relief (MPR) by Treatment <=10 Minutes
88; 91 0.9567
SECONDARY
Time to Meaningful Pain Relief (MPR) by Treatment <=15 Minutes
230; 212 0.4253
SECONDARY
Time to Meaningful Pain Relief (MPR) by Treatment <=30 Minutes
613; 503 0.0038 sig
SECONDARY
Time to Meaningful Pain Relief (MPR) by Treatment <=45 Minutes
983; 864 0.0012 sig
SECONDARY
Time to Meaningful Pain Relief (MPR) by Treatment <=60 Minutes
1139; 1047 0.0074 sig
SECONDARY
Use of Standard Rescue Medication
39; 41 0.8444
SECONDARY
Medication Performance Assessment 30 Minutes Post-treatment
49; 16; 125; 104; 378; 304 <0.0001 sig
SECONDARY
Medication Performance Assessment 60 Minutes Post-treatment
160; 119; 371; 313; 508; 565 <0.0001 sig
SECONDARY
Breakthrough Pain Preference Questionnaire
62; 46; 23; 12
SECONDARY
Patient Global Impression of Change (PGIC) at Visit 7- 1 Month After Open Label Treatment
1.5; 0.6
SECONDARY
Patient Global Impression of Change (PGIC) at Visit 8- 2 Months After Open Label Treatment
1.5; 0.8
SECONDARY
Patient Global Impression of Change (PGIC) at Visit 9- 3 Months After Open Label Treatment
1.7; 0.8
SECONDARY
Patient Global Impression of Change (PGIC) Endpoint
1.5; 0.9
SECONDARY
Clinician Global Impression of Change at Visit 7- 1 Month After Open Label Treatment
1.4; 0.6
SECONDARY
Clinician Global Impression of Change (CGIC) at Visit 8- 2 Months After Open Label Treatment
1.4; 0.7
SECONDARY
Clinician Global Impression of Change (CGIC) at Visit 9- 3 Months After Open Label Treatment
1.6; 0.7
SECONDARY
Clinician Global Impression of Change (CGIC)Endpoint
1.4; 0.7

Summary

Evaluate the efficacy of treatment with the fentanyl buccal tablet (FBT) compared with immediate release oxycodone treatment in alleviating breakthrough pain (BTP) in opioid tolerant patients with chronic pain.

Eligibility Criteria

Key Inclusion Criteria

  • The patient has chronic pain of at least 3 months duration associated with any of the following conditions: diabetic peripheral neuropathy, postherpetic neuralgia, traumatic injury, complex regional pain syndrome, back pain, neck pain, fibromyalgia, chronic pancreatitis, osteoarthritis, rheumatoid arthritis, or cancer. Other chronic painful conditions may be evaluated for possible inclusion.
  • The patient is currently using at least one of the following: at least 60 mg of oral morphine/day, or at least 25 mcg of transdermal fentanyl/hour, or at least 30 mg of oxycodone/day, or at least 8 mg of hydromorphone/day, or an equianalgesic dose of another opioid/day as ATC therapy for at least 7 days before administration of the first dose of study drug.
  • The patient is willing to provide written informed consent, including a written opioid agreement form, to participate in this study.
  • Women must be surgically sterile, 2 years postmenopausal, or, if of childbearing potential, using a medically accepted method of birth control and agree to continued use of this method for the duration of the study.
  • Any patient with cancer should have a life expectancy of at least 3 months.
  • The patient reports an average PI score, over the 24 hours prior to screening, of 6 or less (0=no pain through 10=pain as bad as you can imagine) for their chronic pain.
  • The patient experiences, on average, at least 1 and less than 5 BTP episodes per day while taking ATC opioid therapy, and on average, the duration of each BTP episode is less than 4 hours during the screening period.
  • The patient currently uses opioid therapy for alleviation of BTP episodes, occurring at the location of the chronic pain, and achieves at least partial relief.
  • The patient must be willing and able to successfully self administer the study drug, comply with study restrictions, complete the electronic diary, and return to the clinic for scheduled study visits as specified in this protocol.

Key Exclusion Criteria

  • The patient has uncontrolled or rapidly escalating pain as determined by the investigator or has pain uncontrolled by therapy that could adversely impact the safety of the patient or that could be compromised by treatment with study drug.
  • The patient has a recent history (within 5 years) or current evidence of alcohol or other substance abuse.
  • The patient has known or suspected hypersensitivities, allergies, or other contraindications to any ingredient in either study drug.
  • The patient has a diagnosis of chronic headache or migraine as the primary painful condition with associated BTP.
  • The patient has cardiopulmonary disease that would, in the opinion of the investigator, significantly increase the risk of treatment with potent synthetic opioids.
  • The patient has medical or psychiatric disease that, in the opinion of the investigator, would compromise the patient's safety or collected data.
  • The patient has suicidal ideation at screening or has a history of suicidal ideation within 1 year or history of suicide attempt within 2 years before screening, or a diagnosis of bipolar disorder or history of schizophrenia
  • The patient is expected to have surgery during the study that will impact the patient's chronic pain and/or BTP.
  • The patient has had therapy before study drug treatment that, in the opinion of the investigator, could alter pain or response to pain medication.
  • The patient is pregnant or lactating.
  • The patient has participated in a previous study with FBT.
  • The patient has participated in a study involving an investigational drug in the prior 30 days.
  • The patient is currently using FBT or oral transmucosal fentanyl citrate for BTP.
  • The patient is currently using immediate-release oxycodone for BTP and is unwilling to undergo re-titration.
  • The patient has received a monoamine oxidase inhibitor (MAOI) within 14 days before the first treatment with study drug.
  • The patient has any other medical condition or i
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00813488). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search